Focused On-demand Library for Monoacylglycerol lipase ABHD6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

2-arachidonoylglycerol hydrolase; Abhydrolase domain-containing protein 6

Alternative UPACC:

Q9BV23; B2R7Y9; Q6ZMF7


Monoacylglycerol lipase ABHD6, also known as 2-arachidonoylglycerol hydrolase, plays a pivotal role in lipid metabolism by hydrolyzing medium-chain saturated monoacylglycerols, including 2-arachidonoylglycerol. This activity is crucial for regulating endocannabinoid signaling pathways. ABHD6 also exhibits lysophosphatidyl lipase activity, with a preference for lysophosphatidylglycerol, and is the primary enzyme for bis(monoacylglycero)phosphate (BMP) catabolism, a key player in intraluminal vesicle formation and lipid sorting.

Therapeutic significance:

Understanding the role of Monoacylglycerol lipase ABHD6 could open doors to potential therapeutic strategies, especially in disorders related to lipid metabolism and endocannabinoid signaling.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.